Vor Biopharma, Inc. VOR 深 滬
已收盤 12-05 16:00:00 美东时间
8.18
-0.150
-1.80%
華盛通- 最 高8.43
- 今 開8.43
- 成交量 24.61万股
- 最 低 7.91
- 昨 收 8.33
- 總市值 5596.02万
- 52周最高 65.80
- 市盈率 靜 --
- 換手率 3.60%
- 52周最低 2.622
- 委 比 47.52%
- 總股本 684.11万
- 歷史最高 1272.40
- 量 比 0.58
- 振 幅 6.24%
- 歷史最低 2.622
- 每 手 1
- 風險率 13.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
Wedbush Assumes Vor Biopharma at Neutral, Announces Price Target of $9
Wedbush analyst Martin Fan assumes Vor Biopharma (NASDAQ:VOR) with a Neutral rating and announces Price Target of $9.
11-25 22:06
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(3.33) per share which missed the analyst consensus estimate of $(3.25) by 2.37 percent. This is a 58.39 percent increase over losses of $(8.00) per share from the
11-14 12:27
Vor Biopharma Launches $100M Common Stock Offering
Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has commenced an underwritten public offering of
11-11 05:03
Vor Bio Announced Telitacicept Achieved Primary Endpoint Of Reducing Proteinuria In Stage A Of Phase 3 Clinical Study For IgA Nephropathy In China; Statistically Significant Benefits Also Achieved Across All Key Secondary Endpoints
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profileTelitacicept demonstrated a 55% reduction in
11-09 00:55
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio granted stock options and RSUs to 20 new employees on October 15, 2025, as inducements to employment. The stock options, totaling 113,478 shares with an exercise price of $30.22, and RSUs for 24,319 shares, vest over four years. Options vest 25% after one year, with remaining shares vesting monthly; RSUs vest quarterly. The grants align with Nasdaq rules and the 2023 Inducement Plan. Vor Bio focuses on developing treatment for autoimmune ...
10-31 20:30
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Vor Bio's Collaborator, RemeGen, Presents 48-Week Open-Label Extension Data From Phase 3 Study In China Evaluating Telitacicept In Patients With gMG At AANEM Annual Meeting
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living
10-29 23:03
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Vor Bio announced positive 48-week open-label extension (OLE) results from RemeGen's Phase 3 study in China evaluating telitacicept in generalized myasthenia gravis (gMG). Patients achieved significant improvements in MG-ADL and QMG scores, with all telitacicept-treated patients showing a mean reduction of -7.5 in MG-ADL and 96.2% reaching ≥3-point improvement. Telitacicept demonstrated consistent efficacy and a favorable safety profile, supporti...
10-29 15:01
